CD37 and non-Hodgkin lymphoma: In preclinical studies, IMGN529 has shown robust antitumor activity in CD37-positive NHL models [17, 19], thus providing a rationale for its clinical evaluation as targeted therapy for the treatment of B-cell malignancies.